Abstract | BACKGROUND: MATERIAL AND METHODS: A total of 39 systemically healthy patients with GAgP were evaluated in this randomized clinical trial. Periodontal parameters were recorded at the baseline during the 1st, 3rd and 6th month. Patients received either 400 mg of moxifloxacin per os once daily or 500 mg of metronidazole and 500 mg amoxicillin per os three times daily for 7 days consecutively. RESULTS: No significant differences between groups were found in any parameters at the baseline. Both groups led to a statistically significant decrease in all clinical periodontal parameters compared to the baseline (PI; p<0.001 and GI, PD, BOP, CAL, p<0.01). There were no differences between the 1st and 3rd months or the 3rd and 6th months for clinical parameters in the groups. Also, no intergroup difference was observed in any parameters at any time, except the gingival index at 6th months. CONCLUSIONS: Systemic administration of moxifloxacin as an adjunct to non-surgical treatment significantly improves clinical outcomes and provides comparable clinical improvement with less adverse events to that of combination of amoxicillin and metronidazole in the treatment of GAgP.
|
Authors | Esra Guzeldemir-Akcakanat, Cem-Abdulkadir Gurgan |
Journal | Medicina oral, patologia oral y cirugia bucal
(Med Oral Patol Oral Cir Bucal)
Vol. 20
Issue 4
Pg. e441-9
(Jul 01 2015)
ISSN: 1698-6946 [Electronic] Spain |
PMID | 26034931
(Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Anti-Infective Agents
- Fluoroquinolones
- Metronidazole
- Amoxicillin
- Moxifloxacin
|
Topics |
- Adult
- Aggressive Periodontitis
(drug therapy)
- Amoxicillin
(administration & dosage)
- Anti-Infective Agents
(administration & dosage)
- Drug Therapy, Combination
- Female
- Fluoroquinolones
(administration & dosage)
- Follow-Up Studies
- Humans
- Male
- Metronidazole
(administration & dosage)
- Moxifloxacin
- Young Adult
|